



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra



u^b

b
UNIVERSITÄT
BERN

Assessing vaccine-induced correlates of protection: Antigen-specific readouts versus system vaccinology

Professor Artur Summerfield

*Chair of Veterinary Immunology
Vetsuisse Faculty, University of Bern*

&

Institute of Virology and Immunology

*European Veterinary Vaccinology Workshop,
May 9-10, 2016, Ghent, Belgium*



**VETERINARY
VACCINOLOGY
NETWORK**



Overview of this workshop

1. Classical readouts of adaptive immune responses
 - Antibodies as correlates of protection (COP)
 - T cells as COP
2. System vaccinology

Correlates of protection: general definitions and considerations

1. Correlates of protection (CoPs): markers which statistically correlates with vaccine efficacy. Are used to predict the protective value of a vaccine.
2. Mechanistic CoP (mCoP): CoP mechanistically and causally responsible for protection
3. Nonmechanistic CoP (nCoP): CoP not involved in the protective effects induced by the vaccine
4. CoPs are valid only for a defined vaccine, species, age group...
5. Understanding pathogenesis is required to define CoP's


Human CoP

Vaccine	Test	Level required
Anthrax	Toxin neutralization	1,000 IU/ml
Diphtheria	Toxin neutralization	0.01–0.1 IU/ml
Hepatitis A	ELISA	10 mIU/ml
Hepatitis B	ELISA	10 mIU/ml
Hib polysaccharides	ELISA	1 µg/ml
Hib conjugate	ELISA	0.15 µg/ml
Human papillomavirus	ELISA	ND ^b
Influenza	HAI	1/40 dilution
Japanese encephalitis	Neutralization	1/10 dilution
Lyme disease	ELISA	1,100 EIA U/ml
Measles	Microneutralization	120 mIU/ml
Meningococcal	Bactericidal	1/4 (human complement)
Mumps	Neutralization?	ND
Pertussis	ELISA (toxin)	5 units
Pneumococcus	ELISA; opsonophagocytosis	0.20–0.35 µg/ml (for children); 1/8 dilution
Polio	Neutralization	1/4–1/8 dilution
Rabies	Neutralization	0.5 IU/ml
Rotavirus	Serum IgA	ND
Rubella	Immunoprecipitation	10–15 mIU/ml
Tetanus	Toxin neutralization	0.1 IU/ml
Smallpox	Neutralization	1/20
Tick-borne encephalitis	ELISA	125 IU/ml
Tuberculosis	Interferon	ND
Varicella	FAMA gp ELISA	≥1/64 dilution; ≥5 IU/ml
Yellow fever	Neutralization	1/5
Zoster	CD4 ⁺ cell; lymphoproliferation	ND

^a Also see the text.



^b ND, not defined.

Immunopathogenesis versus protective immune responses




Question: What is the relationship of fecal scores and the inflammatory status in the gut?

Understanding the protective immune response



Increased neutrophil recruitment associated with enhanced resistance to infection of piglets by ETEC

Understanding the protective immune response




Increased IL-6 responses are associated with enhanced resistance to infection


Antibody-based CoP

1. ELISA titre: → usually only a nCoP
2. Avidity and affinity: Antigen-antibody interactions are non-covalent based on hydrogen bonds, hydrophobic interactions, electrostatic and van der Waals forces. They are therefore reversible.
 - Affinity: strength of interaction between an epitope and paratope.
 - Avidity: accumulated strength of the antibody-antigen complex, dependent on affinity, valency of both the antibody and antigen and structural arrangement
3. Antibody function → mCoP


Antibody functions



Antibody-mediated opsonization of microbes



Human antibody-based CoPs



What is the relationship between opsonization and neutralization?



"I was able to neutralize the stress hormone using chocolate."

Minimum epitope requirements for functional activity of Mab D9 recognizing linear epitope on VP1 of FMDV


POSITION 144 -154 VP1: NEUTRALIZING EPITOPE WITH RECEPTOR BINDING SITE

		<u>Neut</u>	<u>Ops</u>	<u>ELISA</u>
O1 Kaufbeuren	L RGDLQV L AQ K V	+	+++	+
O Bulgaria 1/91	V RGDLQV L AR K A	+	+++	+
O Grece 23/94	V RGDLQV L AR K A	+	+++	+
O Grece 22/96	V RGDLQV L AQ K A	+	+++	+
O Vietnam 7/97	V RGDLQV L AQ K A	+	+++	+
A Macedonia 6/96	T RGDLGQ L AA R T	-	+++	-
A 24 Cruzeiro	R RGDMGS L AA R V	-	+	-
Asia-1 Turkey/2000	R RGDMAAL T Q R L	-	+	-
C-S8cl	A RGDLAHL T T T H	-	++	-
Asia 1 Shamir	R RGDMAAL A Q R L	-	-	-

Antibody-based CoP: what else is important


1. Antibody isotype
2. Antibody location: Mucosal antibodies, colostrum/milk antibodies
3. Broadly cross-reactive antibodies: targeting conserved epitopes
4. Mechanisms of neutralization
5. Frequency of memory B cells → ELISPOT
6. Frequency of plasma cells → ELISPOT

Example for influenza




In adults a titre of 1:40 predicts 80% protection
BUT in children 1:330 predicts 80% protection


T-cell-based CoP



CD4 + helper T lymphocytes during infections



Understand the immune response against you pathogen!



IL-17
dominated
immune
response
induced by
ETEC in
piglets

T-cell-based CoP

1. T-cell readout need in vitro restimulation
2. Frequency of responding cells
3. Phenotype of responding cells:
 - CD4 or CD8,
 - Expression of homing markers ($\alpha 4\beta 7$ integrin for intestinal mucosal homing)
4. T cell function
 - Expression of individual or multiple cytokines
 - Proliferation
 - Killing capacity, perforin expression...
 - Number of epitopes targeted
 - Sequence conservation of epitopes targeted

Proposed immune mechanism in protection by veterinary vaccines

DISEASE	Antibody	T cells
<u>Cytolytic virus infection and extracellular bacterial infections</u>		
FMDV, Bluetongue, Rotavirus, Parvovirus, Rabies, Swine Influenza		
Clostridium, E. Coli...		
<u>Non-cytolytic and persisting viruses and persisting parasites and bacteria</u>		
Neospora		CTL, Th1
Theileria		CTL, Th1
Paratuberculosis, Tuberculosis		Th1
PRRSV, CSFV, BVDV, BHV1, PRV		CTL, IFN γ

essential
important
minor role

Facts on T lymphocytes

1. Specificity:

- Crossreactivity! One TCR can recognize multiple epitopes through molecular mimicry

2. Activation:



- in the draining lymph node!
- 3 divisions per day, total 8-15 to reach peak in 1 week: 10000 fold enrichment
- Differentiation to effector cells (up to 5% of total T-cell pool!)

3. Memory

- only 5% of effector cells differentiate in memory cells
- T cell memory is maintained for long time through homeostatic proliferation (IL-7 and IL-15 mediated)

4. Recirculation: 1-2% of lymphocytes per hour.

Antigen processing and presentation



«Cross-presentation» by dendritic cells for MHC class I

Use of PBMC to assess T-cell immunity

- ☺ Easy preparation, contain all cells required:
 - 70% T cells
 - 10 % B cells
 - 1% dendritic cells (not many but potent!)
- ☹ Presence of innate cells which may give „background“ (NK cells, $\gamma\delta$ T cells): depletion by cell sorting might be required
- ☹ Presence of suppressor cells (monocytes, regulatory T cells)
- ☹ Antigen presentation not always possible or effective

Selection of antigens for in vitro restimulation

1. Live pathogens: possible for some viruses, may be not suitable for complex pathogens.
2. Inactivated pathogens to prevent cytopathogenicity. MHC I presentation?
3. Purified recombinant proteins. MHC I presentation?
4. Peptides. Problem MHC haplotype dependency
5. Gene delivery systems: mRNA transfection, plasmid transfection (works only with cell lines), viral vectors

Consider presence of PAMPS which will influence assay (enhancement or suppression, innate responses, “unspecificity”)


Other important parameters

1. Optimization of medium composition
 1. serum-free medium
 2. Addition of cytokines: IL-2, IL-7
2. Incubation times will depend on antigen system, early or late memory stage
3. Use of frozen cells possible but freezing/thawing procedure needs to be optimized (see Disis et al., 2006 J. Immunol Methods 308). Loss of sensitivity

T-cell assays in veterinary immunology

1. Proliferation assay microplates
 - bulk assays: ^3H -thymidine incorporation, MTT assay,
 - single cell assays: CFSE/Violet Stain, Ki67, BrDU
2. Measurement of activation markers by flow cytometry
3. Cytokine responses:
 - Bulk assay with supernatants: ELISA and Multiplex
 - Bulk assay for frequency: ELISPOT
 - Bulk assay for cytokine mRNA
 - Single cell assay using intracellular cytokine staining by FCM
4. Cytotoxic T-cell assays:
 - Killer assays radioactive (Cr-release assay) or flow cytometry
 - CD107 assay, perforin staining, granzyme B release
 - Tetramer staining (MHC haplotype characterized and tools available)

Proteins produced by antigen-stimulated T cells



Other considerations for CoP based on T-cell assays

1. Due to constant re-circulation of memory cells, the frequency of antigen specific T cells is highly variable in the blood. Repeated sampling may be necessary as well as enough data for a robust statistical analysis.
2. Memory cells are highly heterogenous (Th1, Th2, Treg, Th17, Tcm, Tem, multiple cytokine producers, mucosal T cells...) and identifying them depends on the methodology selected.
3. Correlates of protection can change with time post vaccination and are age-dependent.


Summary of T-cell assays

Column1	equipment	high throughput	time	subset	<i>Identification of</i>		
					function	frequency	labour
3H thymidine	harvester & counter	+++	5-6 d	no	no	no	+
CFSE, VS	FCM	+	5-7 d	yes	no	no	++
Activation markers	FCM	+	1-3 d	yes	no	no	++
ELISPOT	ELISPOT reader	++	2-7 d	no	yes	yes	+
ELISA	ELISA reader	+++	2-4 d	no	yes	no	+
RT-PCR	Real time PCR	++	2-4 d	no	yes	no	++
IC cytokines	FCM	+	2 d	yes	yes	yes	++
CTL assay	counter/FCM	-	7-10 d	no	yes	no	+++
CD107 assay	FCM	+	2 d	yes	yes	yes	++

CoP for influenza vaccines in humans

	Inactivated Influenza Vaccine	Live Attenuated Influenza Vaccine
HAI response	+++	+
Antibody secreting cells	++	+
Memory B cells	+	+
Nasal IgA	-/+	+++
NA antibody	-/+	++
CD4 T cells	++	+++
CD8 T cells	-	+?
Cross protective immunity	-/+	++

IFN- γ ELISPOT response to influenza virus infection



neutralization test

IFN- γ ELISpot


-x- Neutralizing Ab titer

◆ FLUAVsw MOI 0.1

■ mock MOI 0.1

▲ medium


CD4 T-cell cytokine response to influenza virus infection




The porcine CD4 multifunctional T-cell response to influenza virus


B

Boolean Gating							
IFN- γ	+	-	-	+	+	-	+
TNF- α	-	+	-	+	-	+	+
IL-2	-	-	+	-	+	+	+
	single			double			triple



Multifunctional CD8 T-cell response to influenza virus






Naive pigs

Infected pigs


Infected pigs

Infected pigs

**Multifunctional
CD8 T-cell
response to
influenza virus**



Flow activities in vaccinomics




Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Troy D Querec^{1,8}, Rama S Akondy^{1,8}, Eva K Lee², Weiping Cao¹, Helder I Nakaya¹, Dirk Teuwen³, Ali Pirani⁴, Kim Gernert⁴, Jiusheng Deng¹, Bruz Marzolf⁵, Kathleen Kennedy⁵, Haiyan Wu⁵, Soumaya Bennouna¹, Herold Oluoch¹, Joseph Miller¹, Ricardo Z Vencio⁵, Mark Mulligan^{1,6}, Alan Aderem⁵, Rafi Ahmed¹ & Bali Pulendran^{1,7}

A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4—an orchestrator of the integrated stress response—that correlated with and predicted YF-17D CD8⁺ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor *TNFRS17*, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.

Pathway analysis reveals many genes of the IFN pathways being upregulated

a



List of genes correlating with CD8 T cells responses


Gene name	Gene symbol	Gene ID
Solute carrier family 2 (facilitated glucose transporter), member 6	<i>SLC2A6</i>	Hs.244378 Day 7
Eukaryotic translation initiation factor 2 alpha kinase 4	<i>EIF2AK4</i>	Hs.412102 Day 7
Integrin, alpha L (antigen CD11A)	<i>ITGAL/LFA-1</i>	Hs.174103 Day 7
C-terminal binding protein 1	<i>CTBP1</i>	Hs.208597 Day 7
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein	<i>YWHAE</i>	Hs.513851 Day 3
Transcribed locus		Hs.619443 Day 7
Protein phosphatase 1, regulatory (inhibitor) subunit 14A	<i>PPP1R14A</i>	Hs.631569 Day 3
Family with sequence similarity 62 member B	<i>FAM62B</i>	Hs.649908 Day 7
Transcribed locus		Hs.42650 Day 7

List of genes correlating with neutralizing antibody responses

Gene name	Gene symbol	Gene ID
BEN domain-containing 4	<i>BEND4</i>	Hs.120591
Transcribed locus		Hs.139006
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	<i>PFKFB3</i>	Hs.195471
Tumor necrosis factor receptor superfamily, member 17	<i>TNFRSF17</i>	Hs.2556
Tumor protein D52	<i>TPD52</i>	Hs.368433
Transcribed locus		Hs.481166
Kelch repeat and BTB (POZ) domain containing 7	<i>KBTBD7</i>	Hs.63841
Transcribed locus		Hs.649726
Nucleosome assembly protein 1-like 2	<i>NAP1L2</i>	Hs.66180


Systems biology of vaccination for seasonal influenza in humans

Helder I Nakaya^{1,2}, Jens Wrammert^{1,3}, Eva K Lee⁴, Luigi Racioppi^{5,6}, Stephanie Marie-Kunze^{1,2}, W Nicholas Haining⁷, Anthony R Means⁶, Sudhir P Kasturi^{1,2}, Nooruddin Khan^{1,2}, Gui-Mei Li^{1,3}, Megan McCausland^{1,3}, Vibhu Kanchan^{1,3}, Kenneth E Kokko⁸, Shuzhao Li^{1,2}, Rivka Elbein⁹, Aneesh K Mehta⁹, Alan Aderem¹⁰, Kanta Subbarao¹¹, Rafi Ahmed^{1,3} & Bali Pulendran^{1,2,12}




What do you expect will be the main difference between the LIAV and TIV vaccine?

LAIIV response is dominated by IFN-response genes




Molecular signatures that correlate with titers of antibody to TIV

Unfolded protein response:
 helps coping with the large amount of Ig produced in ASCs which is associated with accumulation of misfolded proteins.
 → Enhanced secretion
 → XBP1 is central




ASC response


Heatmap of gene signatures of cells of the human immune system




Gene expression in sorted cells following vaccination with LAIV



Gene expression in sorted cells following vaccination




Molecular signatures that correlate with titers of antibody to TIV




Problem of heterogeneity of responses

A




Which factors other than vaccine component will influence the transcriptomic response?

Factors influencing how a vaccine will perturb the immune system



Biological samples are heterogeneous with respect to underlying cell subsets



Available online at www.sciencedirect.com


ScienceDirect



Computational deconvolution: extracting cell type-specific information from heterogeneous samples

Shai S Shen-Orr^{1,2,3} and Renaud Gaujoux²

Computational deconvolution methodologies enable capturing both cell-centered and system



Available online at www.sciencedirect.com

ScienceDirect

25
Current Opinion in
Immunology


Current Opinion in Immunology

Computational deconvolution: extracting cell type-specific information from heterogeneous samples

Shai S Shen-Orr^{1,2,3} and Renaud Gaujoux²



computational approaches that extract cell type-specific information from heterogeneous sample data



Can we use these reference profiles in
veterinary immunology?

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

Shuzhao Li^{1,2,10}, Nadine Rouphael^{1,3,10}, Sai Duraisingham^{1,2,10}, Sandra Romero-Steiner⁴, Scott Presnell^{5,6}, Carl Davis^{1,7}, Daniel S Schmidt⁴, Scott E Johnson⁴, Andrea Milton⁴, Gowrisankar Rajam⁴, Sudhir Kasturi^{1,2}, George M Carlone⁴, Charlie Quinn^{5,6}, Damien Chaussabel^{5,6}, A Karolina Palucka⁶, Mark J Mulligan^{1,3,7}, Rafi Ahmed^{1,8}, David S Stephens^{1,7}, Helder I Nakaya^{1,2,9} & Bali Pulendran^{1,2,9}

Meningococcus vaccines


PS conjugated to DT

YFV live


Flu killed

Flu live


a




“Strength in numbers: comparing vaccine signatures the modular way”



Construction of blood transcriptional modules (BTMs) through large-scale data integration



Heat map of BTMs (rows) and vaccines (columns) whose expression correlated with antibody response.






BTM correlation profiles displayed three distinct patterns:

1. protein recall response (TIV, MCV4-DT),
2. polysaccharide response (MPSV4, MCV4)
3. primary viral response (YF-17D).



BTM M156.1 correlates with specific antibodies (MCV4 vaccine) day 7 p.v.





System vaccinology in veterinary vaccinology